Press Releases Year None201920182017201620152014 Entasis Announces Positive Phase 2 Data of ETX0914 for the Treatment of Gonorrhea Sep 21, 2016 Entasis Presents Data Supporting the Potential Clinical Utility of ETX2514, a Next-generation Beta-lactamase Inhibitor, at ASM Microbe 2016 Jun 28, 2016 Entasis to Present Preclinical Data on ETX2514, a Next-Generation Beta-lactamase Inhibitor, at ASM Microbe 2016 Jun 15, 2016 Entasis Announces $50 Million Series B Financing led by Clarus Apr 04, 2016 Entasis Announces Appointments to its Scientific and Clinical Advisory Board Dec 15, 2015 Entasis Appoints Robin David Isaacs as Chief Medical Officer Jul 15, 2015 Entasis Debuts with a Portfolio of Drug Candidates to Treat Serious Drug-resistant Bacterial Infections Jul 01, 2015 AstraZeneca to create stand-alone company for small molecule early stage antibiotic R&D Feb 26, 2015 ETX0914 (AZD0914) designated a Qualified Infectious Disease Product (QIDP) and given Fast Track status by US FDA Jun 03, 2014 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Displaying 41 - 49 of 49
Entasis Presents Data Supporting the Potential Clinical Utility of ETX2514, a Next-generation Beta-lactamase Inhibitor, at ASM Microbe 2016 Jun 28, 2016
Entasis to Present Preclinical Data on ETX2514, a Next-Generation Beta-lactamase Inhibitor, at ASM Microbe 2016 Jun 15, 2016
Entasis Debuts with a Portfolio of Drug Candidates to Treat Serious Drug-resistant Bacterial Infections Jul 01, 2015
ETX0914 (AZD0914) designated a Qualified Infectious Disease Product (QIDP) and given Fast Track status by US FDA Jun 03, 2014
